Lisa Crocker
Overview
Explore the profile of Lisa Crocker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
888
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang J, Yao X, Aouad P, Wang B, Crocker L, Chaudhuri S, et al.
Nat Cancer
. 2025 Jan;
6(2):357-371.
PMID: 39805955
Multiple next-generation molecules targeting estrogen receptor α (ERα) are being investigated in breast cancer clinical trials, encompassing thousands of women globally. Development of these molecules was partly motivated by the...
2.
Lewis G, Li G, Guo J, Yu S, Fields C, Lee G, et al.
Nat Commun
. 2024 Jan;
15(1):466.
PMID: 38212321
Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab...
3.
Chan J, Chan J, Shao L, Stawicki S, Pham V, Akita R, et al.
J Biol Chem
. 2022 Nov;
299(1):102729.
PMID: 36410439
Fibroblast growth factor receptor 1 (FGFR1) is a receptor tyrosine kinase that plays a major role in developmental processes and metabolism. The dysregulation of FGFR1 through genetic aberrations leads to...
4.
Hegde G, de la Cruz C, Giltnane J, Crocker L, Venkatanarayan A, Schaefer G, et al.
Elife
. 2019 May;
8.
PMID: 31144617
Squamous cell carcinomas (SCCs) account for the majority of cancer mortalities. Although TP63 is an established lineage-survival oncogene in SCCs, therapeutic strategies have not been developed to target TP63 or...
5.
Asghar U, Barr A, Cutts R, Beaney M, Babina I, Sampath D, et al.
Clin Cancer Res
. 2017 Jun;
23(18):5561-5572.
PMID: 28606920
Triple-negative breast cancer (TNBC) is a heterogeneous subgroup of breast cancer that is associated with a poor prognosis. We evaluated the activity of CDK4/6 inhibitors across the TNBC subtypes and...
6.
Burgess M, Hwang E, Mroue R, Bielski C, Wandler A, Huang B, et al.
Cell
. 2017 Feb;
168(5):817-829.e15.
PMID: 28215705
Investigating therapeutic "outliers" that show exceptional responses to anti-cancer treatment can uncover biomarkers of drug sensitivity. We performed preclinical trials investigating primary murine acute myeloid leukemias (AMLs) generated by retroviral...
7.
Asundi J, Crocker L, Tremayne J, Chang P, Sakanaka C, Tanguay J, et al.
Clin Cancer Res
. 2015 Apr;
21(14):3252-62.
PMID: 25862760
Purpose: Chemotherapies are limited by a narrow therapeutic index resulting in suboptimal exposure of the tumor to the drug and acquired tumor resistance. One approach to overcome this is through...
8.
Leong S, Liang W, Wu Y, Crocker L, Cheng E, Sampath D, et al.
Mol Pharm
. 2015 Apr;
12(6):1717-29.
PMID: 25853436
B7-H4 has been implicated in cancers of the female reproductive system and investigated for its possible use as a biomarker for cancer, but there are no preclinical studies to demonstrate...
9.
Zak M, Liederer B, Sampath D, Yuen P, Bair K, Baumeister T, et al.
Bioorg Med Chem Lett
. 2015 Jan;
25(3):529-41.
PMID: 25556090
Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program...
10.
Wang W, Elkins K, Oh A, Ho Y, Wu J, Li H, et al.
PLoS One
. 2014 Oct;
9(10):e109366.
PMID: 25285661
Inhibiting NAD biosynthesis by blocking the function of nicotinamide phosphoribosyl transferase (NAMPT) is an attractive therapeutic strategy for targeting tumor metabolism. However, the development of drug resistance commonly limits the...